By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
New agents versus rare endocrine disorders
Spruce Biosciences is currently in mid-to-late-stage clinical development with the CRF1 receptor antagonist, tildacerfont, for treating two endocrine disorders: classic congenital adrenal hyperplasia (CAH) in adults and in children, and polycystic ovary syndrome (PCOS). Tildacerfont is an oral nonsteroidal small-molecule drug. Spruce has long-range plans for additional agents and indications in the same area.